Tramadol: Mechanism of Action, Dose, Side Effects & GPAT Notes

Introduction to Tramadol

Tramadol is an atypical, centrally acting analgesic. Clinicians prescribe it to treat moderate to moderately severe acute and chronic pain. Unlike classical opioids such as morphine and codeine, tramadol has a distinct pharmacology.

For competitive exams like GPAT and NIPER, examiners frequently ask questions about tramadol. Its dual mechanism of action, active metabolite, and seizure risk make it a high-yield topic in analgesic pharmacology.

---

Chemical Nature and Classification

Tramadol is a synthetic 4-phenyl-piperidine analogue of codeine. Chemically, it is a cyclohexanol derivative: (1R,2R)-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexan-1-ol.

Tramadol is marketed as a racemic mixture of two enantiomers:

• (+)-Tramadol: Inhibits serotonin (5-HT) reuptake and acts as a weak mu (μ)-opioid agonist.
• (-)-Tramadol: Inhibits noradrenaline (norepinephrine) reuptake and stimulates alpha-2 adrenergic receptors.

Together, both enantiomers work synergistically to produce effective pain relief with lower respiratory depression than pure opioids.

---

Dual Mechanism of Action

Tramadol produces analgesia via two distinct pathways:

1. Opioid Mechanism

Tramadol binds to mu-opioid receptors on neuronal cell membranes in the central nervous system. This activation opens potassium channels and closes voltage-gated calcium channels. It leads to hyperpolarization and blocks pain transmission along ascending pathways. However, parent tramadol has a very low affinity for mu receptors (roughly 6,000 times less than morphine).

2. Non-Opioid (Monoaminergic) Mechanism

Tramadol blocks the reuptake of norepinephrine (NE) and serotonin (5-HT) in spinal pain pathways. By increasing local levels of NE and 5-HT, it enhances endogenous descending inhibitory pain pathways.

This dual action explains why the pure opioid antagonist naloxone only partially reverses tramadol-induced analgesia.

---

Pharmacokinetics and Metabolism

Key pharmacokinetic features frequently tested in competitive pharmacy exams include:

• Absorption: Well absorbed orally with a bioavailability of 70% to 75% after a single dose. Bioavailability rises to 90% with chronic repeated dosing due to enzyme saturation.
• Distribution: Widely distributed; crosses the blood-brain barrier and placenta. Plasma protein binding is modest (about 20%).
• Metabolism: Tramadol undergoes extensive phase I hepatic metabolism via Cytochrome P450 enzymes:
  • CYP2D6: O-demethylates tramadol to O-desmethyltramadol (M1).
  • CYP3A4: N-demethylates tramadol to N-desmethyltramadol (M2).
• The Active Metabolite (M1): The M1 metabolite is pharmacologically active. It possesses 200 to 300 times higher affinity for mu-opioid receptors than parent tramadol. Poor CYP2D6 metabolizers experience reduced pain relief.
• Excretion: Excreted primarily by the kidneys (about 90% as metabolites and 10% unchanged drug). Elimination half-life is approximately 6 hours.

---

Recommended Dosages

Dosage depends on the severity of pain, patient age, and organ function.

Adult Dosage

• Immediate-Release (IR): 50 mg to 100 mg orally every 4 to 6 hours as needed.
• Maximum Daily Dose (IR): 400 mg per 24 hours.
• Extended-Release (ER): 100 mg orally once daily, titrated upward if required.
• Maximum Daily Dose (ER): 300 mg per 24 hours.

Special Populations

• Geriatric Patients (>75 years): Daily maximum should not exceed 300 mg of immediate-release formulations.
• Renal Impairment (CrCl < 30 mL/min): Increase dosing interval to every 12 hours; daily maximum is 200 mg.
• Severe Hepatic Impairment: 50 mg orally every 12 hours.

---

Adverse Effects and Toxicity

Tramadol has a safer respiratory profile than morphine, but it carries unique risks:

• Common Side Effects: Nausea, vomiting, dizziness, constipation, sedation, dry mouth, and headache.
• Seizures (Convulsions): Tramadol lowers the seizure threshold. Seizures can occur even at therapeutic doses, especially in patients taking antipsychotics, tricyclic antidepressants, or bupropion.
• Serotonin Syndrome: Co-administration with serotonergic agents (SSRIs, SNRIs, MAO inhibitors) can cause hyperthermia, clonus, tremors, and agitation.
• Abuse and Dependence: Lower abuse liability than Schedule II opioids, but physical dependence and psychological addiction can still occur.
• Respiratory Depression: Rare at normal therapeutic doses, but possible in overdose or in ultrarapid CYP2D6 metabolizers.

---

Tramadol vs. Morphine: Key Differences

Parameter	Tramadol	Morphine
Mechanism	Weak $\mu$-agonist + NE/5-HT reuptake inhibitor	Strong $\mu$-opioid receptor agonist
Active Metabolite	M1 (O-desmethyltramadol)	Morphine-6-glucuronide (M6G)
Respiratory Depression	Minimal at therapeutic doses	Significant, dose-dependent
Histamine Release	Very low	High (causes itching, flushing)
Constipation Risk	Mild to moderate	Marked and persistent
Seizure Risk	High (lowers seizure threshold)	Low at standard doses
Naloxone Reversal	Partial (only opioid component)	Complete reversal

---

High-Yield Points for GPAT & NIPER

• Enantiomer roles: (+)-enantiomer inhibits serotonin reuptake; (-)-enantiomer inhibits norepinephrine reuptake.
• M1 Metabolite: Formed by CYP2D6, responsible for the majority of mu-opioid activity.
• Naloxone limitation: Naloxone only partially reverses tramadol toxicity. In fact, naloxone can increase the risk of seizures in tramadol overdose.
• Absolute Contraindications: Acute intoxication with alcohol, hypnotics, central analgesics, or MAO inhibitors used within the last 14 days.
• Pregnancy & Lactation: Crosses the placenta; contraindicated during labor because it can depress neonatal respiration.